ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

First gene therapy costs $850,000

by Ryan Cross
January 8, 2018 | APPEARED IN VOLUME 96, ISSUE 2

The first gene therapy to treat genetic disease approved by the U.S. Food & Drug Administration will cost $850,000. Luxturna, from Spark Therapeutics, is designed to partially restore vision in people with a rare form of inherited blindness. The one-time treatment was expected to cost $1 million or more. Spark will offer rebates to insurance companies if patients do not improve in short- or long-term tests of light sensitivity. Spark is also in talks with the Centers for Medicare & Medicaid Services about letting government or commercial drug payers foot the bill in installments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment